An Immunomedics therapy for an aggressive form of breast cancer won FDA approval on Wednesday. It’s the company’s first regulatory nod, and it covers a product expected to become a blockbuster seller. Morris Plains, NJ-based Immunomedics (NASDAQ: [[ticker:IMMU]]) developed the drug, sacituzumab govitecan (Trodelvy), as a treatment for treat triple negative breast cancer. This form … Continue reading “Immunomedics Triple Negative Breast Cancer Drug Wins Early FDA Nod”
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)
The start of a potentially big biomedical breakthrough is blooming within all of us. Drug research aiming to turn bacteria into microbiome therapies now spans programs aiming to address gut disorders, autism, cancer, and more. Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the … Continue reading “Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)”
Cara Therapeutics Itching Drug Scratches Off Goals of Phase 3 Test
A Cara Therapeutics drug developed to treat the severe itching experienced by patients receiving hemodialysis has met the main goal of a second late-stage study, setting up the experimental medicine for regulatory filings in the US and Europe. Cara (NASDAQ: [[ticker:CARA]]) is testing its injectable drug, difelikefalin (Korsuva), in patients who have moderate-to-severe chronic kidney … Continue reading “Cara Therapeutics Itching Drug Scratches Off Goals of Phase 3 Test”
Rockwell Medical President & CEO Paul Resigns, Ellison Named Successor
Rockwell Medical (NASDAQ: [[ticker:RMTI]]) announced Monday that Stuart Paul has resigned as president and CEO. Paul, who has held the company’s top executive post since 2018, has also stepped down from the Wixom, MI-based company’s board of directors. No reason was given for the resignation. Russell Ellison, who joined Rockwell Medical’s board in January, was named … Continue reading “Rockwell Medical President & CEO Paul Resigns, Ellison Named Successor”
PTC Therapeutics Promotes Matthew Klein, Eric Pauwels to C-Suite
Rare disease drug developer PTC Therapeutics (NASDAQ: [[ticker:PTCT]]) has promoted Matthew Klein to chief development officer. Klein joined the South Plainfield, NJ, biotech last year as global head of gene and mitochondrial therapies. He was previously CEO and chief medical officer of BioElectron Technology. PTC acquired some of BioElectron’s assets in 2019. In other moves, … Continue reading “PTC Therapeutics Promotes Matthew Klein, Eric Pauwels to C-Suite”
FDA Approves Incyte Drug, First Ever for Rare Bile Duct Cancer
The FDA has granted speedy approval for an Incyte drug developed to treat cholangiocarcinoma, a rare cancer affecting the bile ducts. The regulatory nod for the drug, pemigatinib (Pemazyre), comes more than a month earlier than the anticipated May 30 decision date and it makes the pill the first FDA-approved treatment for cholangiocarcinoma. The decision … Continue reading “FDA Approves Incyte Drug, First Ever for Rare Bile Duct Cancer”
Lantern Pharma IPO File Illuminates Plan to “Rescue” Failed Cancer Drugs
A growing number of drug developers are embracing artificial intelligence as a tool for finding new medicines. Lantern Pharma is betting the technology can also resurrect failed cancer drugs and it is now preparing an initial public stock offering to support their development. Lantern filed its IPO paperwork late Thursday. The Dallas-based company set a … Continue reading “Lantern Pharma IPO File Illuminates Plan to “Rescue” Failed Cancer Drugs”
TearClear Taps Former Shire Executive Robert Dempsey as CEO
Eye drug developer TearClear has appointed Robert Dempsey to serve as its CEO. Demsey was most recently global head of ophthalmology at Shire, which was acquired by Takeda Pharmaceutical (NYSE: [[ticker:TAK]]). TearClear says Dempsey’s hire comes as the company approaches the initial close of a Series B round of funding that could reach up to … Continue reading “TearClear Taps Former Shire Executive Robert Dempsey as CEO”
Imago BioSciences Adds Edgardo Baracchini as Chief Business Officer
Edgardo Baracchini has been appointed chief business officer of Imago Biosciences. His business development experience includes positions at Xencor (NASDAQ: [[ticker:XNCR]]), Metabasis Therapeutics, Elitra Pharmaceuticals, and Agouron Pharmaceuticals. San Francisco-based Imago develops treatments for bone marrow diseases. The company’s lead program, bomedemstat, is in mid-stage testing in myelofibrosis.
Ex-Regeneron Exec Graham Named Evelo Bio Chief Development Officer
Neil Graham has joined Evelo Biosciences (NASDAQ: [[ticker:EVLO]]) as its chief development officer. He was most recently vice president of immunology and inflammation at Regeneron Pharmaceuticals (NASDAQ: [[ticker:REGN]]). Graham’s experience also includes positions at Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]) and Trimeris. Evelo is developing oral biologic drugs that address the small intestinal axis, which plays a … Continue reading “Ex-Regeneron Exec Graham Named Evelo Bio Chief Development Officer”
Five Prime Therapeutics Taps Foundation Med’s Thomas Civik as New CEO
Thomas Civik has been appointed president and CEO of Five Prime Therapeutics (NASDAQ: [[ticker:FPRX]]). He comes to the South San Francisco biotech from Foundation Medicine, where he was chief commercial officer. Civik will also join Five Prime’s board of directors. William Ringo, interim CEO since last September, will step down from the C-suite and continue … Continue reading “Five Prime Therapeutics Taps Foundation Med’s Thomas Civik as New CEO”
With Harvard Tech and $5M, PIC Therapeutics Takes Aim at Cancer
Some of the targets in cancer research are visible and well known, but they’re hard to hit with new drugs all the same. PIC Therapeutics is developing medicines aiming for one particularly elusive group of proteins, and the startup’s early research has attracted financial support from some prominent names in the life sciences industry. PIC … Continue reading “With Harvard Tech and $5M, PIC Therapeutics Takes Aim at Cancer”
GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year
[Updated, 3:13 p.m. See below.] Pharmaceutical giants GlaxoSmithKline and Sanofi are teaming up on COVID-19 research, aiming to combine their respective technologies in a new vaccine that could start clinical trials in coming months. The full details of the agreement, which was announced Tuesday, are still being finalized. But the companies say the vaccine would … Continue reading “GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year”
Ex-Celgene Exec Brownstein Named Chief Medical Officer of Cellectis
Cellectis (NASDAQ: [[ticker:CLLS]]) has appointed Carrie Brownstein to serve as its chief medical officer. She worked most recently at Celgene as vice president of global clinical research and development and therapeutic area head for myeloid diseases. Celgene was acquired by Bristol Myers Squibb (NYSE: [[ticker:BMY]]) last year. Brownstein’s experience also includes positions at Regeneron Pharmaceuticals … Continue reading “Ex-Celgene Exec Brownstein Named Chief Medical Officer of Cellectis”
Blackstone Pays Alnylam $1B to Grab a Stake in RNAi Drug Inclisiran
Seven years ago Alnylam Pharmaceuticals sold rights to one of its preclinical drugs, gaining upfront cash and $180 million in potential milestone payments, plus royalties, for a therapy taking a novel approach to lowering cholesterol. On Monday, the company announced the sale of half of the royalties it’s owed to private equity firm Blackstone for … Continue reading “Blackstone Pays Alnylam $1B to Grab a Stake in RNAi Drug Inclisiran”
AstraZeneca Wins First FDA Drug Nod for NF1, a Rare Genetic Disorder
An AstraZeneca drug designed to block tumor growth is now approved as a treatment for neurofibromatosis type 1 (NF1), a rare inherited disorder that leads to tumors on nerves throughout the body. The FDA’s Friday decision for the drug, selumetinib (Koselugo), makes it the first approved treatment for NF1. It’s also the latest twist in … Continue reading “AstraZeneca Wins First FDA Drug Nod for NF1, a Rare Genetic Disorder”
Adaptive Biotechnologies Names Mark Adams Chief Technical Officer
Adaptive Biotechnologies (NASDAQ: [[ticker:ADPT]]) has appointed Mark Adams to serve as its chief technical officer. He was most recently managing director of healthcare advanced analytics at SVB Leerink. Adams is succeeding Sean Nolan, who will remain at Seattle-based Adaptive, taking on a new role as distinguished engineer. Adaptive is developing therapies based on insight into … Continue reading “Adaptive Biotechnologies Names Mark Adams Chief Technical Officer”
Tango Therapeutics Appoints Beckman as Chief Financial Officer
Daniella Beckman is now the permanent chief financial officer of Tango Therapeutics after holding the role in an interim capacity. Her experience includes financial positions at Idenix Pharmaceuticals, Coley Pharmaceuticals, Biogen Idec, and PricewaterhouseCoopers. Cambridge, MA-based Tango recently raised $60 million in Series B financing to support continued development of cancer drugs based on a … Continue reading “Tango Therapeutics Appoints Beckman as Chief Financial Officer”
Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More
The COVID-19 pandemic has stopped enrollment in many clinical trials and postponed the start of others but there is still life in the life sciences sector. The coronavirus research is expected. It’s the other activity that might come as a surprise. Two biotech companies have gone public in the past week; each upsized its offering and … Continue reading “Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More”
Pfizer, BioNTech Say mRNA COVID-19 Vaccine Trials May Start This Month
Multiple COVID-19 vaccine candidates that use a new technology called messenger RNA are now being readied for clinical trials that Pfizer and BioNTech plan to start in coming weeks. The partnership pairs the mRNA vaccine technology of BioNTech (NASDAQ: [[ticker:BNTX]]) with the vaccine and clinical trial experience of Pfizer (NYSE: [[ticker:PFE]]). The companies said Thursday … Continue reading “Pfizer, BioNTech Say mRNA COVID-19 Vaccine Trials May Start This Month”
Tango Adds $60M in CRISPR Hunt for Synthetically Lethal Cancer Drugs
CRISPR is key to the cancer drugs that Tango Therapeutics is developing, but the startup isn’t out to edit disease-causing genes. Tango uses the technology as a tool for finding drug targets, in research that has yielded a pipeline of compounds. Now it has $60 million to continue that work. The Series B round of … Continue reading “Tango Adds $60M in CRISPR Hunt for Synthetically Lethal Cancer Drugs”
Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics
Some diseases have proven difficult to address using conventional tools of drug discovery that target disease-causing proteins. Roche is placing a $190 million bet on Arrakis Therapeutics, a startup whose technology aims for RNA—carriers of the genetic instructions that make these proteins in the first place. The cash, an upfront payment to Waltham, MA-based Arrakis, … Continue reading “Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics”
Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug
Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-stage compounds, including a depression treatment that failed a pivotal test late last year. The corporate shakeup will eliminate the jobs of 340 employees, or about 53 percent of its staff, Sage … Continue reading “Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug”
Sherlock Bio’s Don Haut Joins AskBio as Chief Business Officer
Gene therapy developer Asklepios BioPharmaceutical (AskBio) has appointed Don Haut to serve as its chief business officer, the same position he held most recently at Sherlock Biosciences. His experience also includes business development roles at Histogenics, The Medicines Company, Smith & Nephew, and 3M (NYSE: [[ticker:MMM]]). Nearly a year ago, Research Triangle Park, NC-based AskBio raised … Continue reading “Sherlock Bio’s Don Haut Joins AskBio as Chief Business Officer”
Immunomedics Taps Ipsen’s Harout Semerjian as President and CEO
Immunomedics (NASDAQ: [[ticker:IMMU]]) has appointed Harout Semerjian to serve as its president and CEO. Semerjian is joining the Morris Plains, NJ-based cancer drug developer from Ipsen, where he is executive vice president and chief commercial officer. His experience also includes positions at Novartis (NYSE: [[ticker:NVS]]). Semerjian will start at Immunomedics on April 16. An FDA … Continue reading “Immunomedics Taps Ipsen’s Harout Semerjian as President and CEO”
Menlo’s Itching Drug Racks Up Two More Trial Failures, Program Ends
An itching drug that was a key part of the merger of Menlo Therapeutics and Foamix Pharmaceuticals has failed two late-stage studies, leading to a halt on further development of the compound. The Menlo (NASDAQ: [[ticker:MNLO]]) drug, serlopitant, was being tested in two Phase 3 clinical trials as a treatment for the itching associated with … Continue reading “Menlo’s Itching Drug Racks Up Two More Trial Failures, Program Ends”
Seres Therapeutics Taps Alkermes’s von Moltke as Chief Medical Officer
Seres Therapeutics (NASDAQ: [[ticker:MCRB]]) has appointed Lisa von Moltke to serve as its executive vice president and chief medical officer. She is joining the Cambridge, MA-based microbiome drug developer from Alkermes (NASDAQ: [[ticker:ALKS]]), where she was senior vice president and head of clinical development. Her experience also includes positions at Sanofi (NYSE: [[ticker:SNY]]) and Takeda … Continue reading “Seres Therapeutics Taps Alkermes’s von Moltke as Chief Medical Officer”
GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months
GlaxoSmithKline has agreed to invest $250 million in infectious disease specialist Vir Biotechnology to launch a COVID-19 R&D alliance that the companies say could advance two experimental therapies to clinical testing this summer. The partnership will leverage antibody technology from Vir (NASDAQ: [[ticker:VIR]]) and genomics expertise from GSK (NYSE: [[ticker:GSK]]). The companies will work together … Continue reading “GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months”
Zentalis Upsizes IPO, Raising $165M for Cancer Drug Clinical Trials
The global economic crash means the window for initial public stock offerings is all but closed but that didn’t stop Zentalis Phamaceuticals from pushing through. The clinical-stage drug developer priced its IPO late Thursday, raising $165.2 million in its stock market debut. Zentalis was able to sell more shares than it expected, and at a … Continue reading “Zentalis Upsizes IPO, Raising $165M for Cancer Drug Clinical Trials”
BioCryst Pharma Appoints Anthony Doyle Chief Financial Officer
Anthony Doyle has been named chief financial officer of BioCryst Pharmaceuticals (NASDAQ: [[ticker:BCRX]]). He is joining the Durham, NC, rare disease drug developer from Worldwide Clinical Trials, where he has been CFO since 2014. His experience also includes several roles at General Electric (NYSE: [[ticker:GE]]). BioCryst is awaiting an FDA decision for berotralstat, a treatment … Continue reading “BioCryst Pharma Appoints Anthony Doyle Chief Financial Officer”
Brainstorm Cell Therapeutics Names Setboun Chief Operating Officer
David Setboun has been appointed executive vice president and chief operating officer of Brainstorm Cell Therapeutics (NASDAQ: [[ticker:BCLI]]). He is joining New York-based Brainstorm from Life Biosciences, where he was vice president of corporate development, strategy and business. Setboun’s experience also includes positions at Biogen (NASDAQ: [[ticker:BIIB]]), AstraZeneca (NYSE: [[ticker:AZN]]), and Eli Lilly (NYSE: [[ticker:LLY]]). … Continue reading “Brainstorm Cell Therapeutics Names Setboun Chief Operating Officer”
Pandion Pulls In $80M as Ulcerative Colitis Drug Advances in Clinic
Pandion Therapeutics emerged in 2018 aiming to reach clinic trials in two years testing its biologic drugs in autoimmune and inflammatory disorders. The company now has $80 million to support a lead program in early-stage testing and a pipeline of potential treatments. Access Biotechnology and Boxer Capital led the Series B round of funding announced … Continue reading “Pandion Pulls In $80M as Ulcerative Colitis Drug Advances in Clinic”
Rhythm Pharma Files Drug Application, Names Hunter Smith Interim CEO
Hunter Smith, chief financial officer of Rhythm Pharmaceuticals (NASDAQ: [[ticker:RYTM]]), has been appointed interim CEO. He takes the place of Keith Gottesdiener, who announced in January that he planned to leave his executive positions and the board of directors after Rhythm submitted a new drug application for setmelanotide. The application was filed with the FDA … Continue reading “Rhythm Pharma Files Drug Application, Names Hunter Smith Interim CEO”
A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy
[Updated 4/10/2020, 3:24 p.m. See below.] Cameron Hewitt’s family celebrates the anniversary of her life not once, but twice yearly: Besides her September birthday, they commemorate a day in March—the anniversary of two-year-old Cameron receiving the gene therapy that gave her a new shot at life. Cameron was born with spinal muscular atrophy (SMA), a … Continue reading “A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy”
Gilead’s Okazaki Named Assembly Bio Chief Legal and Business Officer
Assembly Biosciences (NASDAQ: [[ticker:ASMB]]) is adding another Gilead Sciences (NASDAQ: [[ticker:GILD]]) veteran to its executive team. Jason Okazaki is joining Assembly as its chief legal and business officer. He comes to South San Francisco-based Assembly after 14 years at Gilead, most recently as senior vice president, legal and assistant secretary. Okazaki follows John McHutchinson, the former … Continue reading “Gilead’s Okazaki Named Assembly Bio Chief Legal and Business Officer”
Bioventus CEO Tony Bihl to Retire, Ken Reali Appointed Successor
Bioventus has announced that CEO Tony Bihl will retire on April 30. The Durham, NC-based company has appointed Ken Reali as his successor. He will also join the privately held firm’s board of managers starting on April 20. Reali is coming to Bioventus from Utah-based Clinical Innovations, where he is president and CEO. His experience … Continue reading “Bioventus CEO Tony Bihl to Retire, Ken Reali Appointed Successor”
Axsome Plans to Try Again After Failure in Treatment-Resistant Depression
An experimental Axsome Therapeutics drug for treatment-resistant depression has fallen short of the main goal of a late-stage test. But the company says the pill is showing enough promise to warrant trying another Phase 3 study. Axsome (NASDAQ: [[ticker:AXSM]]) tested its drug, AXS-05, in patients with major depressive disorder who had previously failed to respond … Continue reading “Axsome Plans to Try Again After Failure in Treatment-Resistant Depression”
Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance
Sanofi is joining the array of companies pursuing a COVID-19 vaccine based on messenger RNA (mRNA), an experimental genetic technology intended to coax the body’s cells into producing proteins that treat a disease or spark immunity to one. Sanofi (NYSE: [[ticker:SNY]]) announced Friday that it will develop COVID-19 vaccine candidates with Translate Bio (NASDAQ: [[ticker:TBIO]]), … Continue reading “Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance”
Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More
Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible. Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials or postpone studies that have not yet started. Eli Lilly (NYSE: [[ticker:LLY]]) said that … Continue reading “Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More”
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
A multiple sclerosis drug that came to Bristol Myers Squibb via its acquisition of Celgene last year was approved Thursday but don’t expect it to reach patients any time soon. The company says the drug’s launch will be delayed due to the coronavirus pandemic. The Bristol (NYSE: [[ticker:BMY]]) drug, ozanimod (Zeposia), is one of the … Continue reading “FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch”
AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics
After years of research, technology for silencing a gene—stopping it from producing a disease-causing protein—has reached patients. AstraZeneca is now angling for a position in this burgeoning field through an alliance with Silence Therapeutics, a biotech developing such gene-silencing drugs. According to deal terms announced Wednesday, AstraZeneca (NYSE: [[ticker:AZN]]) will pay London-based Silence (LON: [[ticker:SLN]]) … Continue reading “AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics”
Chrono Therapeutics Top Executive David Happel Joins Cognoa as CEO
David Happel has been appointed CEO of digital therapeutics developer Cognoa. Brent Vaughan, Cognoa’s co-founder and former CEO, will move into a role at venture capital firm Morningside Group, the Palo Alto, CA-based startup’s largest investor. He will also continue to advise Cognoa. Happel joins the company from Chrono Therapeutics, a digital health startup that … Continue reading “Chrono Therapeutics Top Executive David Happel Joins Cognoa as CEO”
CytomX Taps Ex-Alder Bio Exec Campoy as Chief Financial Officer
CytomX Therapeutics has appointed Carlos Campoy to serve as its chief financial officer, the same position he held most recently at Alder BioPharmaceuticals, which was acquired by Lundbeck last year. Campoy’s experience also includes positions at Allergan (NYSE: [[ticker:AGN]]) and Eli Lilly (NYSE: [[ticker:LLY]]). South San Francisco-based CytomX develops antibody cancer drugs. This week, the … Continue reading “CytomX Taps Ex-Alder Bio Exec Campoy as Chief Financial Officer”
CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas
CytomX Therapeutics is teaming up with Astellas Pharma in a research and development alliance focused on developing new cancer immunotherapies based on its antibody technology. Under deal terms announced late Monday, Astellas is paying CytomX (NASDAQ: [[ticker:CTMX]]) $80 million up front. South San Francisco-based CytomX will conduct and finance the research up to the selection … Continue reading “CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas”
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
A type 2 diabetes drug marketed by Boehringer Ingelheim and Eli Lilly has fallen short of a bid to expand the medicine’s approval to patients who have type 1 diabetes. The FDA on Friday rejected the application for the drug, empagliflozin (Jardiance), for use in addition to insulin as a treatment for type 1 diabetes … Continue reading “FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes”
GSK Veteran Paul Wren Joins Escape Bio as Chief Scientific Officer
Escape Bio, a biotech developing therapies for neurodegenerative disorders, has appointed Paul Wren to serve as its chief scientific officer. Wren was most recently senior director of neuroscience discovery at GlaxoSmithKline (NYSE: [[ticker:GSK]]). His experience also includes positions at Pfizer (NYSE: [[ticker:PFE]]) and Novartis (NYSE: [[ticker:NVS]]) subsidiary Sandoz. The most advanced program from San Francisco-based … Continue reading “GSK Veteran Paul Wren Joins Escape Bio as Chief Scientific Officer”
Emulate Taps PerkinElmer’s Corbett as CEO, Gets Cash for Commercial Push
“Organ-on-a-chip” startup Emulate has appointed Jim Corbett to serve as its new CEO. Corbett joins the Boston-based company from PerkinElmer, where he was executive vice president and president of discovery & analytical solutions. At Emulate, he succeeds founding CEO James Coon. Emulate has developed tiny chips lined with human cells that can be used to … Continue reading “Emulate Taps PerkinElmer’s Corbett as CEO, Gets Cash for Commercial Push”
Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More
The financial markets are tumbling, event cancellations are mounting, and sports leagues are suspending their seasons. March Madness is in full swing but not in any way that people wanted or expected. The World Health Organization this week declared that the COVID-19 outbreak was serious enough to classify as pandemic. The toll on public health … Continue reading “Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More”
G1’s Demaree Jumps to Karyopharm for Chief Commercial Officer Job
John Demaree is joining Karyopharm Therapeutics (NASDAQ: [[ticker:KPTI]]) as its chief commercial officer, the same position he held most recently at G1 Therapeutics (NASDAQ: [[ticker:GTHX]]). His experience also includes positions at Astellas Pharma, Abbott Laboratories (NYSE: [[ticker:ABT]]), Novartis (NYSE: [[ticker:NVS]]), and Eli Lilly (NYSE: [[ticker:LLY]]). Newton, MA-based Karyopharm recently reported positive results from a Phase … Continue reading “G1’s Demaree Jumps to Karyopharm for Chief Commercial Officer Job”
Pfizer’s Gupta Joins G1 Therapeutics as Chief Commercial Officer
G1 Therapeutics (NASDAQ: [[ticker:GTHX]]) has appointed Soma Gupta to serve as its chief commercial officer. She was most recently vice president of global marketing for rare disease at Pfizer (NYSE: [[ticker:PFE]]). Durham, NC-based G1 has submitted a rolling application for FDA approval of its lead drug, trilacilib, as a treatment for patients with small cell … Continue reading “Pfizer’s Gupta Joins G1 Therapeutics as Chief Commercial Officer”